Employees Provident Fund Board Increases Stake in Duopharma Biotech Berhad

Strategic Insights -

The Employees Provident Fund Board has acquired an additional 100,000 shares in Duopharma Biotech Berhad, increasing its indirect stake in the company to 8.874%. The acquisition was made on September 3, 2024, through Citigroup Nominees (Tempatan) Sdn. Bhd. The Employees Provident Fund Board now holds a total of 85,362,274 shares in Duopharma Biotech Berhad.

Key Takeaways:

  • The Employees Provident Fund Board has acquired an additional 100,000 shares in Duopharma Biotech Berhad, increasing its indirect stake in the company to 8.874%.
  • The acquisition was made on September 3, 2024, through Citigroup Nominees (Tempatan) Sdn. Bhd.
  • The Employees Provident Fund Board now holds a total of 85,362,274 shares in Duopharma Biotech Berhad, comprising multiple holdings through different nominees.
  • The substantial securities holder details are as follows:

+ Employees Provident Fund Board (KIB-ESG-EQ) - 350,000 shares

+ Citigroup Nominees (Tempatan) Sdn. Bhd. (various accounts) - 42,549,529 shares

  • The acquisition is likely to have a significant impact on the company's capital structure and dividend policy.

Statistics:

  • Number of shares acquired: 100,000
  • Total number of shares held by Employees Provident Fund Board: 85,362,274
  • Indirect stake of Employees Provident Fund Board in Duopharma Biotech Berhad: 8.874%
  • Date of acquisition: September 3, 2024
  • Date notice received by listed issuer: September 6, 2024